TICKERNERD
Menu
REGNREGNHealthcare · Biotechnology

REGN Stock Forecast: Regeneron Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$819
+0.68% on the day

The 28 Wall Street analysts covering Regeneron Pharmaceuticals, Inc. hold a median 12-month price target of $900 — +9.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 28 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$83.7B
Ticker Nerd rank
94/ 100
Median analyst target
$900
Analysts covering
28
Revenue$4.3B+16.7% y/y
Operating income$1.4B
Net income$1.3B
Free cash flow$521.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.0%
1M
+9.1%
YTD
+6.5%
1Y
+26.0%
From 52W high
−3.9%
From 52W low
+36.5%
$600
$852
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

REGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Regeneron Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
94/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
95
Revisions
94
Volatility
91
Momentum
87
Quality
82
Issuance
78
Growth
65
Accruals
39
Size
3

Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (39): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (3): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

REGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on REGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$600$700$800$900$1,000$1,100Jan 26Apr 26Jul 26Oct 26REGNHigh $1,030Median $900Low $730

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says28 analysts
19 Buy8 Hold1 Sell
Low $730Median $900High $1,030

The green dot is the last close — the median target sits +9.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
21 Oct 2026TD CowenMaintainsBuy$960 → $980
19 Oct 2026Piper SandlerMaintainsOverweight$854 → $865
15 Oct 2026UBSUpgradeBuy$660 → $978
8 Oct 2026RBC CapitalMaintainsSector Perform—
8 Oct 2026RBC CapitalMaintainsSector Perform$737 → $810
7 Oct 2026Morgan StanleyMaintainsEqual-Weight$758 → $779
7 Oct 2026Morgan StanleyMaintainsEqual-Weight—
7 Oct 2026Truist SecuritiesMaintainsBuy$772 → $780
7 Oct 2026Truist SecuritiesMaintainsBuy—
6 Oct 2026JP MorganMaintainsOverweight—
6 Oct 2026JP MorganMaintainsOverweight$900 → $950
1 Oct 2026Argus ResearchUpgradeBuy$850
1 Oct 2026Argus ResearchUpgradeBuy—
1 Oct 2026JefferiesMaintainsBuy$870 → $930
1 Oct 2026JefferiesMaintainsBuy—
29 Sept 2026RBC CapitalReiteratesSector Perform—
29 Sept 2026RBC CapitalReiteratesSector Perform$737
10 Sept 2026HSBCMaintainsBuy—
10 Sept 2026HSBCMaintainsBuy$800 → $920
17 Aug 2026Leerink PartnersMaintainsMarket Perform$641 → $824

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

REGN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

REGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Regeneron Pharmaceuticals, Inc. returned +26.0% against +13.6% for the S&P 500, dividends included.

REGN vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130Jan 26Apr 26Jul 26Oct 26REGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

REGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+28.3%
Analysts raising
9
Analysts cutting
1
Fundamentals

Regeneron Pharmaceuticals, Inc. (REGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
20.2×

Cheaper than 37% of US stocks

Price / sales
5.4×

Cheaper than 22% of US stocks

Price / book
2.6×

Cheaper than 35% of US stocks

EV / EBITDA
16.1×

Cheaper than 20% of US stocks

Growth & margins
Revenue growth (YoY)
16.7%

Higher than 65% of US stocks

Earnings growth (YoY)
−6.8%

Higher than 29% of US stocks

Gross margin
86.6%

Higher than 95% of US stocks

Operating margin
33.1%

Higher than 88% of US stocks

Net margin
27.9%

Higher than 87% of US stocks

Returns & dividend
Return on equity
14.0%

Higher than 72% of US stocks

Return on assets
6.5%

Higher than 83% of US stocks

Dividend yield
0.5%

Higher than 65% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Regeneron Pharmaceuticals, Inc. (REGN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Regeneron Pharmaceuticals, Inc. has a market value of $83.7B and an enterprise value of $75.9B.

  • Revenue in the twelve months to 30 June 2026: $15.5B. The latest quarter grew 16.7% year on year.

  • Net income over the same four quarters: $4.3B, a 27.9% net margin.

  • Diluted earnings per share, trailing twelve months: $40.46.

  • Free cash flow in the twelve months to 30 June 2026: $3.6B, after $920.9M of capital spending.

  • Regeneron Pharmaceuticals, Inc. spent $3.9B on share buybacks and $378.5M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 103.1M.

  • Trailing P/E: 20.2×; forward P/E: 12.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.46%, paying out 9% of earnings.

  • Regeneron Pharmaceuticals, Inc. employs 15,410 people — $1.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 29 Oct 2026

Data provided by Twelve Data

Peers

REGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
REGNRegeneron Pharmaceuticals, Inc.$83.7B94
MRNAModerna, Inc.$85.5B78
VRTXVertex Pharmaceuticals, Inc.$134.4B77
RVMDRevolution Medicines, Inc.$39.4B49
RPRXRoyalty Pharma Plc$37.3B86
ALNYAlnylam Pharmaceuticals, Inc.$30.7B52
ROIVRoivant Sciences Ltd.$26.6B36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Regeneron Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest REGN news & analysis

Regeneron Earnings Preview: Dupixent Is Booming, But It's Still Overvalued

Seeking Alpha · 28 Oct 2026negative

Seeking Alpha’s earnings preview says Dupixent is growing strongly, but rates Regeneron Sell at $808 and estimates fair value at about $675. It cites Dupixent’s 2031 patent expiration, biosimilar risks, and legacy product declines that offset EYLEA HD gains.

Why it matters — The article’s view of Regeneron’s valuation and the durability of product growth hinges on whether franchise erosion slows enough to support future cash flow.

Here's Why Regeneron (REGN) is a Strong Value Stock

Zacks Investment Research · 26 Oct 2026positive

Zacks Investment Research’s headline describes Regeneron as a strong value stock. The excerpt explains that Zacks Style Scores are a feature of its Zacks Premium research service for identifying stocks across value, growth, and momentum styles.

Why it matters — REGN watchers may note the favorable value-stock characterization and the research feature cited by Zacks.

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

GlobeNewsWire · 25 Oct 2026positive

Longer-term data with nearly four years of follow-up showed that adjuvant Libtayo (cemiplimab) was associated with a further reduction in the risk of death, from 14% to 37%, among patients with high-risk cutaneous squamous cell carcinoma. The finding was reported despite 88% of patients in the placebo arm crossing over to Libtayo after recurrence.

Why it matters — The results provide additional long-term overall-survival data on Regeneron’s Libtayo in the adjuvant treatment of high-risk CSCC.

FAQ

Frequently asked questions about REGN stock

What is the REGN stock price forecast for 2026-2027?

The 28 Wall Street analysts covering Regeneron Pharmaceuticals, Inc. have a median 12-month price target of $900, with estimates ranging from $730 to $1,030. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is REGN stock a buy right now?

Of the 28 analysts covering Regeneron Pharmaceuticals, Inc., 19 rate it a Buy, 8 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Regeneron Pharmaceuticals, Inc. 94 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank REGN?

As at 28 Oct 2026, Regeneron Pharmaceuticals, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).

Will REGN stock go up?

No one can know that. What the data says: the median 12-month target from 28 analysts implies +9.9% from the last close, and Ticker Nerd's factor model ranks Regeneron Pharmaceuticals, Inc. 94 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the REGN stock forecast for 2030?

No analyst covering Regeneron Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for REGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $730 to $1,030 over the next 12 months.

How has REGN stock performed over the past year?

Regeneron Pharmaceuticals, Inc. returned +26.0% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Regeneron Pharmaceuticals, Inc. do?

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for people with serious diseases.

What is the latest news on REGN?

The most recent item we track (Seeking Alpha, 28 Oct 2026): "Regeneron Earnings Preview: Dupixent Is Booming, But It's Still Overvalued". Seeking Alpha’s earnings preview says Dupixent is growing strongly, but rates Regeneron Sell at $808 and estimates fair value at about $675. It cites Dupixent’s 2031 patent expiration, biosimilar risks, and legacy product declines that offset EYLEA HD gains.

Company

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for people with serious diseases. Its portfolio spans treatments in eye care, immunology, oncology, cardiovascular and metabolic disease, infectious disease, hematology, and rare disorders. The company is known for combining laboratory research, clinical development, and in-house manufacturing to advance biologic therapies and antibody-based medicines. Regeneron also works on product candidates across multiple therapeutic areas, supporting a broad drug pipeline alongside its marketed medicines. Regeneron Pharmaceuticals, Inc. plays an important role in the healthcare market through its focus on specialty therapies designed for complex and often chronic medical conditions.

CEO Dr. Leonard S. Schleifer M.D., Ph.D. · 15,410 employees · United States · https://www.regeneron.com